Now showing items 1-10 of 11
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
OBJECTIVE: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS: Meta-analysis of phase III trials of licensed DMDs for ...
FLAIR* for the non-invasive histological diagnosis of MS
Objectives: To explore whether FLAIR* is superior to current MRI criteria for a diagnosis of MS using MRI datasets acquired at a single time point and a standard field strength (3T). Background: Current MRI criteria to ...